The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.
One of these suggested stocks features a dividend yield topping 10%.
11h
Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research
Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...
By Yadarisa Shabong Jan 20 (Reuters) - Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV ...
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for ...
Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.
“Stories of Hope” shares the stories of the people and scientists at the forefront of advancing medical science and pushing ...
All three of these stocks sport dividend yields above 6%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback